Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
Become a Member | Sign in
Home>News>This Article

Victrix CMCC Chooses Cresset’s Software for Drug Discovery Consulting Projects

Published: Friday, June 28, 2013
Last Updated: Friday, June 28, 2013
Bookmark and Share
Cresset’s software will help Victrix clients to carry out structure based drug design projects.

Under a new agreement, Victrix CMCC will use Cresset’s software for their computational chemistry consulting projects.

Cresset’s Spark, Forge and Torch software will help Victrix clients to carry out structure based drug design projects and build predictive 3D SAR models for lead identification.

“Victrix is very pleased to be able to offer our clients access to Cresset's software,” says Dr Adam Kallel, CSO of Victrix. “Cresset’s field based software significantly expands our ability to help clients with programmes that have little or no structural information.”

Dr Kallel adds, “I have been a believer in field based methodology since I began work in the pharmaceutical industry and I was an early adopter of the Cresset technology. I believe the XED force field that underlies Cresset’s software provides the ability to model molecules and their molecular fields in a way that is as close to high level quantum mechanics as possible, giving valuable insights into structure reactivity relationships. I strongly recommend its use and am very pleased to provide this functionality to Victrix clients."

“We are delighted that Victrix has chosen to use Cresset’s software for their consulting projects,” says Dr Robert Scoffin, CEO of Cresset. “Our field based approach of using 3D shape and electrostatics to understand molecular function is particularly valuable when there is no information available about the protein target. We look forward to Victrix clients experiencing the difference our software will make to their research.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Cresset Donates to Novartis’ TExts to Sub-Saharan Africa Project
Project donates textbooks to Kenyan university libraries.
Tuesday, September 30, 2014
CloudScientific Appointed as Cresset’s Distributor in China
CloudScientific appointed as distributor of computational chemistry software.
Friday, July 11, 2014
Locating and Explaining ‘Activity Cliffs’ in SAR Datasets
Activity Miner from Cresset is an intuitive SAR interpretation tool, identifying key 3D structural and electrostatic changes that impact molecular activity.
Monday, September 16, 2013
Cresset Announces new International Sales Team
Cresset has expanded its computational chemistry software sales team in the U.S. and Europe.
Thursday, September 09, 2010
Cresset Announces Appointment of Rob Scoffin as new CEO
Rob replaces Beatrice Leigh, who will now become non-executive Chairman of the Board.
Monday, April 26, 2010
Cresset Expands Sales Pipeline Potential through CambridgeSoft Alliance
CambridgeSoft sells Cresset’s FieldAlign and FieldTemplater products using its direct, telesales and ecommerce channels.
Monday, April 20, 2009
Scientific News
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Potential Persistent Tuberculosis Treatment
Researchers have discovered several first-in-class compounds that target hidden TB infections by attacking a critical process the bacteria use to survive in the hostile environment of the lungs.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Giant Molecules Inhibit Ebola Infection
European researchers have designed a "giant" molecule formed by thirteen fullerenes covered by carbohydrates which, by blocking this receptor, are able to inhibit the cell infection by an artificial ebola virus model.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Fighting Pain with Ketamine
Researchers at the Texas A&M Health Science Center are using ketamine, a drug that already exists as an anesthetic, to treat pain.
Possible New Treatment for Neurodegenerative Diseases Found
Researchers at the University of Liverpool have found that a well-established anti-epileptic drug could also be used as a treatment for neurodegenerative diseases.
Breast Cancer Drug Beats Superbug
Tamoxifen helps white blood cells clear multidrug-resistant bacteria in lab and mouse studies.
Have Your Drug Nano-Delivered Via Microbubble
A UC engineering professor is working to develop effective nanoparticle-bubble drug delivery systems to access precise locations in the body to treat medical conditions such as cancer, eye disease and spinal disc degeneration.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos